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E-mail address: hannun@musc.edu (Y.A. Hannun).The plasma membrane (PM) is a major resource for production of bioactive lipids and contains a
large proportion of the cellular sphingomyelin (SM) content. Consequently, the regulation of SM lev-
els at the PM by enzymes such as sphingomyelinase (SMase) and SM synthase 2 (SMS2) can have pro-
found effects – both on biophysical properties of the membrane, but also on cellular signaling. Over
the past 20 years, there has been considerable research into the physiological and cellular functions
associated with regulation of SM levels, notably with regards to the production of ceramide. In this
review, we will summarize this research with particular focus on the SMases and SMS2. We will out-
line what biological functions are associated with SMmetabolism/production at the PM, and discuss
what we believe are major challenges that need to be addressed in future studies.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The plasma membrane (PM) of the cell has the important
function of separating the inner cellular environment from the
extracellular space. However, it also has a crucial role in communi-
cation between cells and their environments, being involved in
processes such as subcellular trafﬁcking, signal transduction, and
metabolite exchange. Like all membranes, the PM is comprised of
a lipid bilayer with a hydrophobic core and hydrophilic surfaces
– in this case, an extracellular surface and a cytosolic surface.
Although conceived primarily (but not exclusively) as a single
homogeneous domain in the classic ﬂuid mosaic model [1], the
PM is now thought to contain membrane microdomains termed
‘lipid rafts’. Comprised of laterally segregated sphingomyelin
(SM) and cholesterol tightly packed into liquid-ordered domains
that exist in the surrounding ‘liquid disordered’ phase, it has been
suggested that rafts have an important role in signal transduction
and other cellular processes. This is discussed in more depth in the
following reviews [2,3]. However, despite the abundance ofchemical Societies. Published by E
e; LDL, low density lipopro-
Mase, neutral sphingomyeli-
; PM, plasma membrane; SK,
ingomyelinase; SMS1, sphin-
thase 2; S-SMase, secretoryliterature investigating rafts, their existence and functional roles
remain an issue of heated discussion.
As in most organelles, there is also an asymmetry within the PM
lipid bilayer such that the compositions of the extracellular and
cytosolic leaﬂets are signiﬁcantly different. The outer leaﬂet is
reported to be enriched in phosphatidylcholine (PC), SM and glyco-
sphingolipids whereas the inner leaﬂet is abundant in phosphoin-
ositides, phosphatidylserine (PS), phosphatidylethanolamine and
phosphatidic acid [4,5]. Classically, the PM cholesterol is thought
to be portioned relatively evenly between the two layers [5]; how-
ever, a recent study suggests the preponderance of cholesterol
localizes to the inner leaﬂet [6]. Thus, with such distinct lipid envi-
ronments, it is not difﬁcult to imagine that metabolism of lipids
within each leaﬂet may produce distinct physiological outcomes.
The PM contains a large portion of the cellular SM [7]. Not only
is it a component of lipid rafts, but SM can be metabolized to
ceramide, a bioactive lipid in its own right, but also a precursor
molecule to other signaling lipids and a central hub of the sphingo-
lipid network (reviewed in [8]). Conversely, the production of SM
from ceramide and PC by the enzyme SM synthase can serve to
regulate signal transduction through reducing ceramide levels,
but also increasing levels of DAG and SM. Thus, both sphingomye-
linase (SMases) and SM synthases can act as signaling switches at
the PM. Moreover, as SM and ceramide have differing properties,
the metabolism of SM to ceramide or production of SM from
ceramide can consequently also have important biophysical effects
on the membrane itself. Here, we will outline the current literaturelsevier B.V. All rights reserved.
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SMases and sphingomyelin synthase 2 (SMS2). In addition, we will
review the biological functions associated with SM metabolism/
production at the PM, and will brieﬂy discuss the major challenges
to be addressed in the future.2. Bacterial sphingomyelinase
Many pathogenic bacteria produce proteins with neutral SMase
activity despite the fact that they are unable to synthesize sphingo-
lipids themselves. The bacterial sphingomyelinases (bSMases) are
secretory proteins and are part of a larger family of phospholipases
released into the environment where they are able to utilize host
cell lipids to exert cytotoxic effects [9]. Importantly, the identiﬁca-
tion and puriﬁcation of bSMases provided the sphingolipid ﬁeld
with useful tools with which to study the effects of endogenous
ceramide generation through exogenous addition of bSMases to
cell culture, a practice still in use today. However, it should be cau-
tioned that the effects of exogenous bSMases on PM lipids can ex-
tend beyond SM, causing hydrolysis of other membrane lipids such
as PC. Thus, these effects should be taken into account when inter-
preting results.
2.1. Properties
Currently, bSMase genes have been identiﬁed from a number of
bacteria such asBacillus cereus, Staphylococcus aureus, Listeria ivano-
vii, Leptospira interrogans and the Pseudomonas sp. Strain TK4. In
addition, bSMase activities have been characterized fromHelicobac-
ter pylori and Mycobacterium tuberculosis (see [10] and references
therein). It should also be noted that a number of other members
of the bacterial phospholipase family often possess both phospho-
lipase C (PLC) and SMase activities such as PlcHR from P. aerugonosa
[11], a-toxin fromClostridium perfringens [12], and PlcB fromListeria
monocytogenes [13]. Many of the identiﬁed bacterial SMases share
common properties with molecular masses of between 33 and
38 kDa although there are exceptions such as the bSMases from
TK4 (58 kDa) and Le. interrogans (63 kDa) (see [10]). The SMase
activity of all these proteins has neutral pH optima and is depen-
dent on divalent cations such as Mg2+ and Mn2+, whereas Ca2+
and Sr2+ are both ineffective for hydrolysis [14]. Based on the
homology of the active site residues, the bSMases were classiﬁed
as members of the DNAse 1 superfamily and this was subsequently
conﬁrmed with the recent solving of the crystal structures of
bSMases from B. cereus, L. ivanovii and b-toxin from S. aureus
[14–16]. These structures also shed light on the catalytic mecha-
nisms, and it was proposed that SM hydrolysis proceeds by acid–
base catalysis through a pentavalent phosphorus transition state.
For a more detailed description of the proposed mechanism, the
reader is referred to [14]. Notably, the conserved catalytic site res-
idues throughout many of the N-SMases in higher organisms sug-
gest a common catalytic mechanism. Finally, bSMases from B.
cereus, S. aureus and L. ivanovii all contain a hydrophobic b hairpin
structure that is necessary for interaction of the bSMases with cell
membranes and liposomes and, presumably, functions to bring the
SMase into close proximity to its substrate on the outer membrane
[14]. However, it should also be noted that this region is not wholly
conserved in the bSMases from Le. interrogans, the Pseudomonas sp.
strain TK4 or S. epidermis which suggests that there are additional
mechanisms for bSMase interaction with the membrane [15,16].
2.2. Bacterial SMase and hemolysis
The best characterized action of bSMases is their ability to
induce hemolysis – the breaking open of red blood cells withsubsequent release of hemoglobin into the surrounding ﬂuid. Thus
far, hemolytic activity has been reported for all known bSMases
[9,10] and many studies have observed that the susceptibility of
erythrocytes to undergo hemolysis correlates with their cellular
SM content i.e. sheep erythrocytes (50% SM) readily undergo
bSMase-induced hemolysis whereas, for example, horse erythro-
cytes (10% SM) are much more resistant [9]. In addition, kinetic
analysis of the bSMase from Staphylococcus schleiferi found that
the SMase activities and hemolytic activities were closely related
and showed identical Michaelis–Mentin kinetics [17]. Thus, it
was inferred that SMase activity plays a crucial role in hemolysis.
Subsequent conﬁrmation of this came from genetic studies of the
b-toxin from S. aureuswhere it was found that mutation of key cat-
alytic residues abolished SMase activity, and prevented all hemo-
lytic activity [16]. Moreover, similar studies in a-toxin from C.
perfringens and PlcHR2 from Pseudomonas aeruginosa, proteins that
possesses both PLC and SMase activities, have found that the
SMase activities of these enzymes are more crucial for hemolysis
than the PLC activities [12,18]. Taken together, these results sug-
gest that bSMase-mediated hydrolysis of SM at the PM is crucial
for their hemolytic activity.
It is well established that the sensitivity of erythrocytes to
hemolysis to certain agents increases when cells are cooled to
4 C following incubation with the hemolytic agents at 37 C [18]
although the mechanism underlying this phenomenon termed
‘hot–cold hemolysis’ has remained unclear. Given the crucial role
of SMase activity in hemolysis as described above, it was suggested
that SM metabolism at the membrane is important for hot–cold
hemolysis. Indeed, an early study postulated that such SM hydro-
lysis generated ‘fragile’ erythrocytes so that, on cooling, the altered
membrane properties caused sufﬁcient stress to result in the lysis
[19]. More recent studies have begun to probe this question fur-
ther. A recent study that analyzed erythrocyte ghost membranes
following hemolysis induced by PlcHR2 from P. aeruginosa and
found the presence of large ceramide-rich domains; importantly,
these domains were ﬂuid at 37 C but rigid at 4 C [18]. Moreover,
ceramidase treatment reduced the presence of these domains and,
consequently, reduced hot–cold hemolysis induced by PlcHR2 [18].
Taken together, these results indicate that the formation of cera-
mide-rich domains by a bacterial SMase activity plays an impor-
tant role in the phenomenon of hot–cold hemolysis.
2.3. Bacterial SMase and other mammalian cell types
In addition to their deleterious effects on erythrocytes, studies
have reported that bSMases are also cytotoxic to other mammalian
cell types albeit to varying degrees. An early study found that
bSMases from S. aureus, B. cereus, and Streptomyces sp. were selec-
tively cytotoxic to human monocytes yet had little effects on via-
bility of human granulocytes, ﬁbroblasts, or lymphocytes despite
being able to degrade SM efﬁciently in these cells [20]. In contrast,
studies with Sph2 from Le. interrogans reported cytotoxic effects on
mouse lymphocytes, mouse macrophages, and human liver cells in
addition to its hemolytic properties [21] while a more recent study
with SMase (b-toxin) from S. aureus reported cytoxicity against
proliferating T-cells; importantly, both hemolysis and leukotoxic-
ity were dependent on enzymatic activity [16]. Moreover, PlcHr2
from P. aeruginosa, which is both a SMase and PC-PLC, was reported
to be selectively cytotoxic to endothelial cells yet was weakly cyto-
toxic to HeLa and A549 cells [22]. Notably, the cytotoxic effect of
PlcHr2 on endothelial cells resulted in suppression of angiogenesis;
however, it was not clear which enzymatic activities were impor-
tant for this effect [11]. In contrast to this, beta-hemoylsin from
S. aureus was found to suppress production of interleukin-8 from
endothelial cells, but did not have effects on cell viability; with re-
gards to the former effect, this was postulated to be a result of SM
D. Milhas et al. / FEBS Letters 584 (2010) 1887–1894 1889hydrolysis as exogenous ceramide addition produced comparable
effects [23]. Taken together, these data suggest that bSMase-med-
iated hydrolysis of SM at the PM can have adverse effects on a
number of mammalian cell types. However, it should be empha-
sized that this is not limited to cytotoxic effects.
2.4. Genetic deletion of bSMase
In addition to the studies outlined above, further evidence for
the important role of SMases in bacterial virulence has come from
studies utilizing knockout strains. For L. ivanovii, genetic knockout
of its SMase, SmcL resulted in a notably weaker hemolysis on blood
agar. More importantly, the knockout strains displayed a marked
decrease in virulence compared to wild-type strains when injected
into mice [13]. Moreover, intracellular proliferation of the knock-
out strain in MDCK cells was markedly reduced, and it was found
that SmcL played an important role in allowing the bacteria to en-
ter the cytoplasm though disruption of the phagosomal compart-
ment [13]. This important role of SmcL in L. ivanovii was further
underscored when it was reported to be part of a larger pathoge-
nicity locus, LIPI-2; interestingly, LIPI-2 appeared to be species
speciﬁc to L. ivanovii [24]. Similar knockout studies with S. aureus
have reported that the SMase functions as a virulence factor in
infection models of the mouse mammary gland [25] and the rabbit
cornea [26] with knockout out strains showing reduced pathoge-
nicity in both cases. More recent research using intranasally
infected mice found that SMase plays a crucial role in lung injury
induced by S. aureus by enhancing neutrophil inﬂux into the lung
and alveolar space, and vascular leakage of serum proteins into
the extravascular spaces [27].3. Secretory sphingomyelinase
The existence of a secreted SMase in mammalian systems was
ﬁrst postulated following observations of SMase activity in serum
plasma [28]. However, unlike the many bSMases that display
homology to the mammalian neutral SMases, the mammalian se-
creted SMase (S-SMase) was found to be an alternatively trafﬁcked
form of the lysosomal acid SMase (L-SMase), which is responsible
for the hereditary storage disorder, Niemann–Pick disease (the
reader is referred to other reviews on this enzyme). Whereas
L-SMase is targeted to the lysosomes through mannose-phosphor-
ylation, S-SMase is not mannose-phosphorylated and is instead
trafﬁcked out of the cell by means of the default Golgi secretory
pathway [29]. Although there is a paucity of studies on S-SMase,
there has been suggestion of regulated S-SMase secretion but the
manner in which this occurs remains poorly understood [30].
3.1. Properties
As might be expected, S-SMase has some distinct characteristics
compared to its lysosomal counterpart. Although both enzymes are
zinc hydrolases, L-SMase becomes tightly co-ordinated to Zn2+ ion
en route to the lysosome whereas S-SMase requires an external
source of Zn2+ for full activity [29]. In addition, although both pro-
teins are N-glycosylated, S-SMase exhibits a complex type pattern
in comparison with the high mannose N-glycan composition of
L-SMase [29]. Unlike its lysosomal relative, S-SMase has also been
demonstrated to hydrolyze lipoprotein-bound SM at neutral pH;
while this is perhaps surprising, given the neutral pH of the extra-
cellular milieu, the molecular basis for this in S-SMase remains
poorly understood, particularly given the reported narrow pH
sensitivity of L-SMase [31]. Thus, mammalian S-SMase seems to
function in an extracellular environment and, consequently, could
function to act in both an autocrine or paracrine fashion tometabolize SM at the outer leaﬂet of the PM. As of yet, however,
there have been very few studies directed at understanding the
speciﬁc functional roles of S-SMase.
3.2. Elevation of serum S-SMase activity
Despite the paucity of information on the functional roles of S-
SMase, a number of studies have reported elevations of serum S-
SMase activity in pathological states including type II diabetes
[32], sepsis [33], chronic heart failure [34], and hypercytokinemia
[35]. This has also been observed in response to ionizing radiation
therapy in cancer patients [36]. However, in all cases, the mecha-
nisms that underlie secretion of the S-SMase protein are poorly
understood. Moreover, research thus far has not addressed either
the cellular consequences or the subsequent biological implica-
tions associated with enhanced S-SMase secretion.
3.3. S-SMase and LDL sphingomyelin
Although beyond the scope of this review, it should also be
mentioned that there is considerable evidence implicating S-SMase
in the aggregation of low density lipoproteins (LDL), an early event
in atherosclerosis, through mediating hydrolysis of LDL-bound SM.
This is covered in more detail in [37].
3.4. Translocation of L-SMase
In addition to the S-SMase discussed above, it is also worth not-
ing that there are reports of metabolism of SM to ceramide at the
PM resulting from an acute translocation of L-SMase, presumably
from the lysosomes to the outer leaﬂet of the PM. This has been
reported in response to a number of stimuli such as UV radiation,
Fas ligand/CD95, cisplatin, and phorbol ester [38–41]. Mechanisti-
cally, this was reported to require phosphorylation of L-SMase on
serine 508 by protein kinase C-d in response to UV and cisplatin
[38,39].
Ceramide generated by acute translocation of L-SMase has been
implicated in cytoskeletal reorganization [38], activation of pro-
apoptotic proteins such as JNK [40], ‘capping’ of Fas receptors in
T-cells [42] and, consequently, apoptosis induced by both UV and
Fas ligand [41,42]. Despite this, there is still limited information
as to how ceramide generated in the PM exerts its effects. Studies
have suggested this is through direct downstream signaling effec-
tors such as protein phosphatases [38]. In contrast, other studies
have centered around the effects of ceramide generation on the
organization of the PM – speciﬁcally through modulation of the
detergent-insoluble membrane microdomains termed ‘lipid rafts’
[43,44]. Notably, a number of studies have indicated that hydroly-
sis of SM in rafts leads to the formation of more stable, ceramide-
enriched domains and this has been reported to occur in response
to a variety of stimuli including UV, CD40, Fas ligand/CD95, viral
and bacterial infection amongst others. Moreover, many of these
studies have demonstrated a necessity for L-SMase in this process
(see [44] and references therein). Thus, in addition to reported
roles for L-SMase in modulating lysosomal enzymes such as
cathepsin D [45], there is growing evidence indicating functional
roles for L-SMase through modulating SM levels at the PM. How-
ever, it should also be noted that it is unclear if translocation of
L-SMase to the PM is part of a broader relocalization of lysosomal
enzymes, or a consequence of speciﬁc regulation of the L-SMase
enzyme itself. Additionally, the acute translocation of L-SMase to
the PM could account for a Zn2+-independent acid SMase activity
that has been reported in some studies [32]. However, as the
molecular identity of protein responsible for this activity is un-
known, strong conclusions cannot be made.
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Neutral sphingomyelinases (N-SMases) are a family of Mg2+-
dependent enzymes that catalyze the hydrolysis of SM into cera-
mide at pH 7.4. Of the three recently cloned mammalian N-SMases
(we use here N-SMase as generic indication of neutral SMases),
only nSMase2 and nSMase3 display in vivo activity. However,
nSMase3 is reported to localize to the endoplasmic reticulum
and the Golgi compartment [46,47]. Thus, in this review, we will
focus on nSMase2.
4.1. Properties
First puriﬁed from mammalian brain, nSMase2 is a membrane-
bound protein of 71 kDa with a C-terminal catalytic domain and
two predicted hydrophobic segments near the N-terminus [48].
In addition, nSMase2 possesses two palmitoylation sites, one lo-
cated between the putative hydrophobic regions and the other
found within the catalytic region, respectively [49]. Although these
palmitoylation sites were reported to be important for PM localiza-
tion, the subcellular localization of nSMase2 remains not fully
determined. It was ﬁrst described as a Golgi-associated protein
potentially involved in the Golgi secretory vesicle trafﬁcking [50]
and, indeed, the endogenous nSMase2 was reported to colocalize
with Golgi markers in both SH-SY5Y neuroblastoma cells and rat
PC-12 cells [48]. However, other studies have indicated a PM local-
ization of overexpressed GFP-, FLAG- or V5-tagged-nSMase2 in
various cancer cell lines [51–54]. Furthermore, stimuli such as
TNFa, H202 and cell conﬂuence were reported to induce nSMase2
translocation from the Golgi to the PM [55,56]. Despite these re-
ported differences, the SM-rich PM most likely represents the ma-
jor site of action of nSMase2. Moreover, nSMase2 is activated by
phosphatidylserine which is enriched in the inner leaﬂet of the
PM [57]. Interestingly, the catalytic domain of nSMase2 is pre-
dicted to be located in the cytosolic leaﬂet of the PM suggesting
the presence of SM in the intracellular side of the membrane
[58]. Although this is contrary to reported lipid asymmetry (see
above), this is very consistent with previous studies reporting a
pool of signaling SM located at the inner PM leaﬂet [59,60]. Within
the PM, N-SMase activity has been detected in detergent-insoluble
fractions of the PM, i.e., rafts/caveolae which are enriched in cho-
lesterol and SM. A possible direct molecular interaction between
nSMase and caveolin-1 has also been suggested as the caveolin-
scaffolding domain of caveolin-1 was reported to inhibit N-SMase
activity [61]. Consistent with this, caveolin-1 overexpression inhib-
ited N-SMase activity and decreased apoptosis in response to
staurosporine [62]. Furthermore, this and other chemotherapeutic
agents such as daunorubicin and cytosine arabinoside augmented
N-SMase activity in raft fractions in human myeloblastic and neu-
ronal cells lines [63–65]. Taken together, this suggests that caveo-
lae/rafts are important for regulation of N-SMase activity, although
the identity of the speciﬁc N-SMase in these studies is unclear.
However, as Goswami et al. recently reported an increase in the
activity of overexpressed nSMase2 in the raft fraction in stauro-
sporine-stimulated oligodendroglioma cells (HOG cells), nSMase2
is a good candidate for the caveolae/raft N-SMase enzyme [66].
4.2. nSMase2 in cell death
Given the reported role of ceramide in programmed cell death,
it is perhaps unsurprising that a number of studies have focused on
the role of N-SMase in this process. Previously, N-SMase activation
has been reported in apoptosis induced by the death receptor Fas
(CD95) and tumor necrosis factor receptor I (TNF-RI). Notably, both
receptors are redistributed to the caveolae/raft fraction of the PM
upon stimulation by their respective ligands. However, althoughN-SMase activation seems to participate in the execution phase
of apoptosis in response to CD95 engagement [67], it appears to
act upstream of mitochondrial events in the TNFR-I signaling path-
way [68]. Although the identity of the N-SMase involved is unclear,
more recent studies have indicated that nSMase2 may participate
in the early events of TNFa-induced apoptosis. By utilizing a mu-
tant TNF-R1, Neumeyer et al., reported a role for nSMase2 in
caspase-3 activation and the subsequent induction of apoptosis
by TNFa [69]. Additionally, the reconstitution of nSMase2 in a
mouse osteosarcoma cell line lacking the endogenous enzyme
restored sensitivity to TNFa [51]. Also, Goswami et al. reported
that overexpression of nSMase2 in staurosporine-stimulated oligo-
dendroglioma cells (HOG cells) led to enhanced cell death [66].
Finally, Tani and Hannun found that nSMase2 overexpression,
through a tetracycline-inducible expression system, potenti-
ated TNF-a-induced cell death of MCF-7 cells (unpublished
observations).
Despite these data, the exact mechanism by which ceramide
generation by nSMase2 leads to the activation of caspases and cell
death remains to be elucidated. The increase of ceramide in lipid
rafts may enhance the recruitment of TNF-RI to the rafts and
potentiate the activation of the receptor. However, N-SMase acti-
vation can also serve as a source for other bioactive sphingolipids.
In particular, a study in nSMase2-deﬁcient human osteosarcoma
cells found that both lactosylceramide production and apoptosis
were reduced in response to TNF-a [70]. This suggests that nSM-
ase2 is upstream of LacCer in the TNFR signaling pathway.
4.3. nSMase2 in trafﬁcking
In addition to the evidence implicating nSMase2 in TNFa-in-
duced cell death, recent studies have also supported a role for
nSMase2 in membrane trafﬁcking. Using both the pharmacological
inhibitor of nSMase2, GW4869, and neuronal cells from the fro/fro
mice (possessing an inactive nSMase2), nSMase2 was implicated in
the TNF-a-induced clustering of NMDA receptors in lipid rafts of
hippocampal neuronal cells. In this study, it was speculated that
rapid ceramide generation at the PM is important for the fusion
of vesicles and insertion of the NMDA receptor into the lipid rafts
[71]. Notably, this is consistent with studies of the PLC/SMase
PlcHR2 (see above) where its hydrolytic activity caused fusion of
vesicles in vitro [22]. In addition, ceramide was found to be en-
riched in exosomes puriﬁed from cell culture medium of mouse
oligodendroglial cells. Notably, inhibition of nSMase2 with
GW4869 or by siRNA reduced exosome release. Although this sug-
gests a role for nSMase2 in the secretory pathway, it was shown
that addition of bSMase to giant unilamellar vesicles (GUVs) re-
sulted in formation of intraluminal vesicles [72]. Thus, it was sug-
gested that nSMase2 may act in the endosomal compartments
giving rise to multivesicular endosomes through formation of
intravesicular membranes. Given the reported localization of nSM-
ase2, this implies intracellular trafﬁcking of nSMase2 from the PM
or Golgi to the recycling endosomes. Although we have recently
found evidence that nSMase2 may trafﬁc from the PM to the recy-
cling endosomes (Milhas and Hannun, unpublished observations),
in some cell types the budding of exosome vesicles occurs in an
endosome-like domain of the PM [73]. Thus, nSMase2 could also
be involved in exosome biogenesis from the PM.
4.4. nSMase2 in inﬂammation
As reviewed recently, nSMase2 plays a role in the inﬂammation
process during aging and in response to IL-1b. Speciﬁcally,
nSMase2 activation enhances IL-1b signaling by preventing the
phosphorylation and ubiquitination of IRAK-1 in a manner depen-
dent on the ceramide-activated protein phosphatase 2 (PP2A)
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stress increases nSMase2 activity during aging [74]. Also, TNF-a-
induced nSMase2 activation is involved in vascular inﬂammatory
responses such as the induction of vascular cell adhesion molecule
(VCAM) and intracellular adhesion molecule (ICAM) in lung epithe-
lial cells [55]. In both cases, the ceramide generated at the PM is
suggested to be a second messenger in the inﬂammatory signaling
pathway.
In contrast, TNF-a-induced endothelial nitric oxide synthase
(eNOS) in human endothelial cells involves the sequential activa-
tion of nSMase2 and sphingosine kinase-1 (SK1) [75]. Thus, it is
implied that the nSMase2-generated ceramide is converted to
sphingosine-1-phosphate through the actions of a ceramidase
and SK1 although the nature of the ceramidase involved remains
to be deﬁned. Consistent with this, nSMase2 was also described
upstream of SK1 in TNFa-induced proliferation of smooth muscle
cells and ﬁbroblasts [76]. Interestingly, in this model matrix
metalloproteinases (MT1-MMP1 and MMP-2) are involved in the
activation of nSMase2 which is consistent with the action of
N-SMase at the PM. Finally, nSMase2 was suggested to be involved
in acute hypoxic pulmonary vasoconstriction whereby the
N-SMase-derived ceramide could act on the K+ or Ca2+ channels
to regulate cell membrane polarization [77]. Taken together, these
studies indicate that the production of ceramide by nSMase2 at the
PM can have dual effects – both as a source of other bioactive
sphingolipids, but also as a signal in its own right.
5. Sphingomyelin synthase 2 (SMS2)
The SM synthases are expressed ubiquitously and catalyze the
bidirectional reaction of choline phosphotransferase converting
ceramide and PC into SM and diacylglycerol (DAG). Two mam-
malian isoforms have been cloned, sphingomyelin synthase 1
(SMS1) and SMS2 [78]. However, as SMS1 localizes solely in
the Golgi apparatus whereas SMS2 is found both at the PM
and in the Golgi, the focus of this part of the review will be
on SMS2.Fig. 1. Schematic of SMmetabolism and production at the plasma membrane. S-SMase, a
(Cer) which, in turn can be metabolized back to SM by SMS2. Alternatively, ceramide ma
(CDase), can be converted to sphingosine which can also ﬂip (and vice versa can ‘ﬂop’). In
be converted to sphingosine (Sph) by CDase and, potentially, on to sphingosine-1-phosp
has ﬂipped from the outer leaﬂet may also be converted to sphingosine-1-phosphate by
the cell to act extracellularly. Thus, small effects on the four major SM-regulating enzym5.1. Properties
SMS2 is an integral membrane protein with six predicted trans-
membrane domains and a C-terminal catalytic site located on the
exoplasmic leaﬂet of the PM [78]. This implies the production of
SM extracellularly from ceramide generated there and, thus,
SMS2 could participate in the SM cycle potentially terminating cer-
amide signals produced from SMase-mediated hydrolysis of SM.
Consistent with this, SMS2 was found responsible for the produc-
tion of cell surface-associated SM in HeLa cells [79]. Moreover, siR-
NA downregulation of SMS2 decreased the level of SM in raft-like
domains of the PM [80] while its overexpression induces the oppo-
site effect [81]. However, the PM is not the sole site of SMS2 action
as studies have reported the presence of active SMS2 in the Golgi
[82] and implicated SMS2 in de novo biosynthesis of SM [79,80].
Notably, these results can also explain the importance of the S-
palmitoylation of SMS2 with regards to the PM localization of
the enzyme but not for its activity [83].
5.2. SMS2 in cell death
Based on its participation in the regulation of lipid-raft struc-
tures SMS2 at the PM has been suggested to be involved in signal
transduction. More speciﬁcally, roles for SMS2 in cell death have
been proposed, although this remains controversial. The genera-
tion of SM at the PM by the overexpression of SMS2 in CHO cells
was reported to enhance TNF-a-induced apoptosis; it was sug-
gested that SM generation in lipid rafts may increase the exposure
of the TNF-R at the surface [81]. Additionally, siRNA downregula-
tion of SMS2 protected THP-1 derived macrophages from LPS-in-
duced apoptosis and this was attributed to a decrease of TLR-4
expression at the cell surface [81]. Thus, the level of SM at the
PM and speciﬁcally in raft microdomains seems to regulate these
events by modulating the cell surface expression of receptors. In
contrast to these data, siRNA against SMS2 potentiated caspases
activation and cell death upon photodynamic therapy in Jurkat
cells [84], potentially through increasing ceramide levels. Thus, itcid SMase (L-SMase) and bSMase can act upon extracellular SM to produce ceramide
y potentially ﬂip to the inner leaﬂet (and vice versa) or, by the actions of ceramidase
contrast, nSMase2 on the inner leaﬂet can hydrolyze SM to ceramide. This also can
hate (S1P) by the actions of sphingosine kinase (SK). Additionally, sphingosine that
SK. Moreover, sphingosine-1-phosphate on the inner leaﬂet may be pumped out of
es can have broader implications on the levels of many bioactive lipids.
1892 D. Milhas et al. / FEBS Letters 584 (2010) 1887–1894seems that SMS2 activity could be pro- or anti-apoptotic depend-
ing on the cell type and the stimulus. However, it should be noted
that SMS activity regulates both the level of the pro-apoptotic cer-
amide and the pro-survival DAG and in opposite directions. Conse-
quently, siRNA knockdown of SMS2 reduced growth of HeLa cells,
with a slight reduction in cell viability, but this was not restored by
the addition of external SM [79]. Thus, decreased SM may not be
the only cause of a growth defect; in particular, a decrease in
DAG may participate to this effect.
5.3. SMS2 in atherosclerosis
More recent data have suggested a promoting role for SMS2 in
atherosclerosis in mice. In this study, SMS2 overexpression in a
transgenic mouse model induced a pro-atherogenic phenotype
characterized by increased plasma non-HDL-SM which induced
an aggregation of non-HDL particles after SMase treatment, an
upregulation of the HDL receptor SR-BI, a decrease of cholesterol
efﬂux and a reduction of plasma apoE level. Reciprocally, SMS2
knockout mice displayed the opposite effects [85,86]. Mechanisti-
cally, SM generation and decreased ceramide in PM rafts conse-
quent to SMS2 activity could be responsible for modulating the
expression of the receptors SR-BI and Apo-E at the cell surface.
However, the effects of SMS2 activity on the level of other sphingo-
lipids such as sphingosine and sphingosine-1-phosphate may also
be involved in the development of atherosclerosis [86]. Finally, the
reported role of SMS2 in NF-jB activation could also contribute to
its pro-atherogenic potential. Notably, the downregulation of SMS2
signiﬁcantly prevented NF-jB activation in response to LPS in mac-
rophages and upon TNFa stimulation of HEK 293 cells [87]. As sug-
gested for the inhibitory effect of SMS2 on cell death induced by
these agonists [81], defects in the recruitment of the TLR-4-MD2
complex and of TNF-RI to lipid rafts was suggested to be the under-
lying mechanism responsible for decreased NF-jD activation.
6. Conclusions
The PM represents the primary source of SM which is ﬁrst bio-
synthesized in the Golgi compartment by the action of the two iso-
forms of SMS (SMS1 and SMS2) and then delivered to the PM by
vesicular transport. At the PM, the levels of SM can be regulated
by multiple enzymes including S-SMase and SMS2 acting in the
outer leaﬂet and nSMase2 located in the inner leaﬂet. Speciﬁcally,
these enzymes regulate the levels of both SM and ceramide which
can also be metabolized to other bioactive sphingolipids such as
sphingosine and S1P as shown schematically in Fig. 1. Moreover,
SMS2 also modulates the levels of PC and DAG. Thus, the effects
of these enzymes may extend far beyond their immediate effects
on SM and ceramide alone. Consistent with the proposed role of
lipid rafts in signal transduction at the PM, both SMS2 and nSM-
ase2 activities in these microdomains appear to be involved in
the modulation of receptor-induced cell death and inﬂammatory
signaling pathways. Thus, the levels of both SM and ceramide at
the PM seem to be important for cellular signaling.
The manipulation of SM and ceramide level at PM by the over-
expression or downregulation of the enzymes involved in their
synthesis and/or hydrolysis, i.e. SMase and SMS has allowed the
identiﬁcation of roles of SMS2 and nSMase2 in speciﬁc biological
functions. However, some contradictory effects have been reported
as, for example, with the role of SMS2 in apoptosis. Although cell
type and stimuli dependence can explain these discrepancies, we
also think that it is important to consider how the extent of
changes in SM and ceramide levels as well as further metabolism
may exert different outcome on the cellular responses. For
instance, a complete depletion of ceramide or SM may profoundlydisturb the structure of the PM and could be deleterious for the cell
as reported by the cytotoxic effect of bSMases. In contrast, a mod-
erate decrease of lipid content may modulate the signaling path-
ways initiated at the PM. We strongly feel that this should be
taken into account when interpreting results.
Finally, a major challenge for the future is to gain a full under-
standing of the speciﬁc SM/Cer species present within the outer
and inner leaﬂets of the membrane, and, more importantly, if the
production of distinct species, or lipids within speciﬁc leaﬂets
has distinct metabolic and physiological consequences for the cell.
This will be imperative if we are to obtain an understanding of the
distinct roles of S-SMase, and SMS2 acting on the extracellular side
of the PM and nSMase2 on the inner leaﬂet. Moreover, as modula-
tion of PM lipids is an early event in the response to many stimuli,
a greater understanding of the lipids at the PM, and the enzymes
that regulate them, is essential for us to fully appreciate the intri-
cacies of signal transduction.
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